Clinical Genomics Banner.png

Clinical

Genomics

Reveal the cause of genetic diseases.

Support your patients completely with accurate information and helpful advice. A definitive diagnosis can provide great relief to patients and their families, especially when they have been searching for answers for a long time.

About

DIPLOIDE has identified genetic variants associated with oncological diseases in more than 250 different genes.

 

DIPLOIDE has a wide range of tests and knowledge available to improve the diagnosis, prognosis, selection and monitoring of cancer. We have specific services for hereditary and somatic cancer, and numerous cancer-specific genetic panels available, such as DIPCANCER, a specially designed panel related to cancer risk. We offer genetic testing for the most common types of diseases, such as breast and colon cancer, and hundreds of unique genetic tests through complete exome (WES) and complete genome sequencing (WGS).

 

DIPLOIDE is a world leader in the diagnosis of rare genetic diseases and has received multiple international accreditations (ISO, CAP and CLIA) that confirm the highest standards for diagnostic tests and reports. Our combined experience with our scientific experience and our medical competence has allowed the application of cutting-edge technologies and the development of a unique multiethnic mutation database.

 

DIPLOIDE has the world's largest mutations database for rare diseases, 57% of which are composed of unpublished variants, we have created and carefully documented all the variants that have clinical relevance for the related symptoms that support the diagnosis accurate of an oncological disease.

DIPLOIDE is dedicated to providing innovative diagnostic services to the clinical oncology community in an effort to enhance the personalized management of the disease. DIPLOIDE research focuses on the development and cutting-edge solutions for the detection of genomic abnormalities in cancer.

 

The unique needs of oncological diagnoses are evolving as rapidly as our understanding of these diseases. At Cancer Genetics, we know that doctors, patients and their families trust us to provide the most advanced tests available. For this reason, we offer tests on several technology platforms and guarantee that all the most relevant tests are available to our customers.

 
Sequencing NGS

Whole Exome Sequencing

01/19 - 01/23

Complete exome sequencing provides information on all genes and identifies changes in DNA by focusing on the most informative regions of the genome, for a rapid and cost-effective diagnostic solution.

Clinical Exome Sequencing

01/19 - 01/23

DIPLOID focuses on the coding part of all genes associated with known clinical phenotypes, including the complete clinical exome. It is our largest NGS panel available, covering more than 3,200 diseases.

Whole Genome Sequencing

01/19 - 01/23

The complete genome sequencing is ideal to find new mutations and identify atypical presentations of a disease, especially in patients with a heterogeneous or atypical phenotype.

 

Reproductive Health

Detecting a disease at an early stage may allow for adequate and timely medical intervention before more serious and sometimes irreversible health problems are caused.

Reproductive Health NGS Panels

Carrier Screening

01/19 - 01/23

Most people can be carriers of a disease that causes changes without knowing it. If both partners are carriers, they have a 25% risk of having an affected child with a recessive genetic disease and a 50% risk that the child will be a carrier like the parents.

Genetic Newborn Screening

01/19 - 01/23

Each year, an estimated 7.9 million babies worldwide are born with birth defects, many of which appear healthy at birth and come from families with no history of the disorder. Many affected babies are not identified until the appearance of severe and often irreversible symptoms later in life.

Arreglo CGH

01/19 - 01/23

La hibridación genómica comparativa es un método citogenético molecular para analizar las variaciones en el número de copias. La matriz CGH nos permite determinar de forma rápida y eficiente la abundancia relativa de secuencias de ácido nucleico en la muestra objetivo.

Biochemical tests and biomarkers

01/19 - 01/23

Biomarkers play an essential role in the diagnosis, prediction and monitoring of the therapy of various metabolic diseases, especially when patients have accessible treatment options.

NGS genomic panel

01/19 - 01/23

NGS Panel Genomic avoids the additional costs of step-by-step analysis of deletion / duplication, exome tracking or genome sequencing, mitochondrial analysis or analysis of new genes associated with the phenotype when new information emerges.

Non-invasive prenatal test

01/19 - 01/23

DIPLOIDE offers genetic, non-invasive prenatal tests (NIPT) to detect the most common fetal chromosomal abnormalities. Our test combines the latest next-generation sequencing technology with expert medical reports.

UHD 1000px DIPLOIDE MINIMALIST logo.png

EXPLORE

LEGAL

CONNECT WITH US

Facebook

Twitter

Instagram

YouTube

Linkedin

© 2020 by DIPLOIDE GENETICS CORPORATE

1440 G St NW Washington, DC 20005

+1 833 DIPLOID

Contact Us